Finally, IBD medications in hepatocyte-derived HepaRG cells significantly reduced the expression of lipogenesis-related genes, such as SREBP-1c, SCD, FAS, ACLY, ACC, and LXRα, contributing to improved blood lipid profiles. This evidence concerns the gene SCD and inflammatory bowel disease.